ChemoCentryx, Inc. (NASDAQ:CCXI) is now up 44.76% compared to a 12-month low of $9.07. We have seen the price to move -3.81% lower and get settled at $13.13 on 4/12/2019. At recent session, it appeared stuck in a range of $13.04 to $13.76. This company shares are 56.66% off its target price of $20.57 and the current market capitalization stands at $675.28M. The recent change has given its price a 12.21% lead over SMA 50 and -12.35% deficit over its 52-week high. The stock witnessed 28.47% gains, 6.66% gains and 30% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CCXI’s volatility during a week at 4.77% and during a month it has been found around 5.7%.

ChemoCentryx, Inc. (CCXI) Top Holders

Institutional investors currently hold around $359 million or 48.4% in CCXI stock. Look at its top three institutional owners: Bvf Inc/Il owns $87.81 million in ChemoCentryx, Inc., which represents roughly 13% of the company’s market cap and approximately 24.46% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,729,701 shares of the stock are valued at $35.84 million. The third largest holder is Wasatch Advisors Inc, which currently holds $30.51 million worth of this stock and that ownership represents nearly 4.52% of its market capitalization.

ChemoCentryx, Inc. 13F Filings

At the end of December reporting period, 39 institutional holders increased their position in ChemoCentryx, Inc. (NASDAQ:CCXI) by some 1,858,125 shares, 59 decreased positions by 1,812,842 and 18 held positions by 23,666,924. That puts total institutional holdings at 27,337,891 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 929,440 shares while 11 institutional investors sold out their entire positions totaling 299,014 shares.

ChemoCentryx, Inc. (NASDAQ:CCXI) Insider Trades

Multiple company employees have indulged in significant insider trading. ChemoCentryx, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Schall Thomas J. has sold 160,000 shares of ChemoCentryx, Inc. (CCXI) in the trading session dated Apr. 02, 2019. These shares are worth $2,195,200 and were traded at $13.72 each. The SEC filing shows that KANAYA SUSAN M performed a sale of 35,000 shares. The EVP, CFO and Sec. disposed these shares by way of transaction on Mar. 27, 2019. The company’s shares were given away at $13.05 per share worth to an income of some $456,750 to the account of KANAYA SUSAN M.

EVP, CFO and Sec., KANAYA SUSAN M, sold 37,893 common shares of ChemoCentryx, Inc. (CCXI) in the open market. In a transaction dated Jan. 22, 2019, the shares were put up for sale at an average price of $12.08, raking in a sum of $457,747. After this sale, 72,853 common shares of CCXI are directly owned by the insider, with total stake valued at $956,560.

In the transaction dated Jan. 10, 2019, a great number of shares sold came courtesy the Chief Bus. Officer & Treasurer; Cappel Markus J. disposed a total of 6,172 shares at an average price of $12, amounting to approximately $74,064. The insider now directly owns 35,441 shares worth $465,340.

ChemoCentryx, Inc. (CCXI) Analyst Guide

Several analysts have released their opinion on ChemoCentryx, Inc. (NASDAQ:CCXI), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].